person · Reporting owner

HAWKINS WILLIAM A

Disclosed activity across 4 companies

Tapewire entity: 38935
SEC CIK: 0001106508

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AVANOS MEDICAL, INC.AVNS · Entity 28189	Director	January 04, 2021	January 06, 2021
BIOGEN INC.BIIB · Entity 1675	Director	June 09, 2026	June 11, 2026
Bioventus Inc.BVS · Entity 4996	Director	June 02, 2026	June 04, 2026
MIMEDX GROUP, INC.MDXG · Entity 5271	Director	June 10, 2026	June 12, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AVANOS MEDICAL, INC.

Report date January 04, 2021 · Filed January 06, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	31,197	Reported balance After 2021-01-04 transaction · row 1 1 source row Row 1 · 2021-01-04 · Grant · Acquired 4,005 · Balance 31,197 F1: Represents restricted share units issued to the reporting person on January 4, 2021 pursuant to the Avanos Medical, Inc. Outside Directors' Compensation Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted share units issued to the reporting person on January 4, 2021 pursuant to the Avanos Medical, Inc. Outside Directors' Compensation Plan.

BIOGEN INC.

Report date June 09, 2026 · Filed June 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	10,365	Reported balance After 2026-06-09 transaction · row 1 1 source row Row 1 · 2026-06-09 · Grant · Acquired 1,505 · Balance 10,365 F1: The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 9, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 9, 2026.

Bioventus Inc.

Report date June 02, 2026 · Filed June 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	297,640	Reported balance After 2026-06-02 transaction · row 1 1 source row Row 1 · 2026-06-02 · Exercise / conversion · Acquired 39,789 · Balance 297,640
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-02 · Exercise / conversion · Disposed 39,789 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2: The RSUs vested on June 2, 2026.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	30,994	Reported balance After 2026-06-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-03 · Grant · Acquired 30,994 · Balance 30,994 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.

F2: The RSUs vested on June 2, 2026.

F3: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.

MIMEDX GROUP, INC.

Report date June 10, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	254,931	Reported balance After 2026-06-10 transaction · row 1 1 source row Row 1 · 2026-06-10 · Grant · Acquired 50,913 · Balance 254,931 F1: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next meeting of shareholders.

Filing footnotes · ownership attribution and instrument terms

F1: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next meeting of shareholders.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 10, 2026 Filed Jun 12, 2026 11:30 UTC	MIMEDX GROUP, INC. MDXG · Entity 5271	GrantCommon Stock	50,913	$3.64	$185,323.32	Disclosure SEC source: 0001376339-26-000042 · wk-form4_1781278199.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 254,931 F1 · shares: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next meeting of shareholders. Read SEC document
June 09, 2026 Filed Jun 11, 2026 21:50 UTC	BIOGEN INC. BIIB · Entity 1675	GrantCommon Stock	1,505	$0.00	$0.00	Disclosure SEC source: 0000875045-26-000065 · form4.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,365 F1 · shares: The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 9, 2026. Read SEC document
June 03, 2026 Filed Jun 4, 2026 16:46 UTC	Bioventus Inc. BVS · Entity 4996	GrantRestricted Stock Units · Derivative	30,994	$0.00	$0.00	Disclosure SEC source: 0001106508-26-000003 · wk-form4_1780605985.xml · derivative · entry 3 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,994 Underlying: Class A Common Stock · 30,994 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F3 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document
June 02, 2026 Filed Jun 4, 2026 16:46 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionRestricted Stock Units · Derivative	39,789	$0.00	$0.00	Disclosure SEC source: 0001106508-26-000003 · wk-form4_1780605985.xml · derivative · entry 2 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 39,789 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on June 2, 2026. F2 · derivative.expiration_date: The RSUs vested on June 2, 2026. Read SEC document
June 02, 2026 Filed Jun 4, 2026 16:46 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionClass A Common Stock	39,789	$0.00	$0.00	Disclosure SEC source: 0001106508-26-000003 · wk-form4_1780605985.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 297,640 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 18, 2025 Filed Jun 23, 2025 18:38 UTC	MIMEDX GROUP, INC. MDXG · Entity 5271	GrantCommon Stock	28,609	$6.47	$185,100.23	Disclosure SEC source: 0001376339-25-000068 · wk-form4_1750718326.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,018 F1 · shares: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders Read SEC document
June 17, 2025 Filed Jun 18, 2025 20:46 UTC	BIOGEN INC. BIIB · Entity 1675	GrantCommon Stock	2,370	$0.00	$0.00	Disclosure SEC source: 0001127602-25-017762 · form4.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,860 Read SEC document
June 03, 2025 Filed Jun 4, 2025 21:29 UTC	Bioventus Inc. BVS · Entity 4996	GrantRestricted Stock Units · Derivative	39,789	$0.00	$0.00	Disclosure SEC source: 0001578563-25-000304 · wk-form4_1749086984.xml · derivative · entry 3 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,789 Underlying: Class A Common Stock · 39,789 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F3 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document
June 02, 2025 Filed Jun 4, 2025 21:29 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionRestricted Stock Units · Derivative	26,493	$0.00	$0.00	Disclosure SEC source: 0001578563-25-000304 · wk-form4_1749086984.xml · derivative · entry 2 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 26,493 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on June 2, 2025. F2 · derivative.expiration_date: The RSUs vested on June 2, 2025. Read SEC document
June 02, 2025 Filed Jun 4, 2025 21:29 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionClass A Common Stock	26,493	$0.00	$0.00	Disclosure SEC source: 0001578563-25-000304 · wk-form4_1749086984.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,851 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 21, 2024 Filed Jun 25, 2024 21:14 UTC	BIOGEN INC. BIIB · Entity 1675	GrantCommon Stock	1,340	$0.00	$0.00	Disclosure SEC source: 0001127602-24-019235 · form4.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,490 Read SEC document
June 11, 2024 Filed Jun 13, 2024 17:25 UTC	Bioventus Inc. BVS · Entity 4996	GrantRestricted Stock Units · Derivative	26,493	$0.00	$0.00	Disclosure SEC source: 0001578563-24-000285 · wk-form4_1718313939.xml · derivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,493 Underlying: Class A Common Stock · 26,493 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F2 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document
June 07, 2024 Filed Jun 11, 2024 20:45 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionRestricted Stock Units · Derivative	30,400	$0.00	$0.00	Disclosure SEC source: 0001578563-24-000268 · wk-form4_1718153100.xml · derivative · entry 2 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 30,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on June 7, 2024. F2 · derivative.expiration_date: The RSUs vested on June 7, 2024. Read SEC document
June 07, 2024 Filed Jun 11, 2024 20:45 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionClass A Common Stock	30,400	$0.00	$0.00	Disclosure SEC source: 0001578563-24-000268 · wk-form4_1718153100.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 05, 2024 Filed Jun 6, 2024 16:17 UTC	MIMEDX GROUP, INC. MDXG · Entity 5271	GrantCommon Stock	23,190	$7.26	$168,359.40	Disclosure SEC source: 0001376339-24-000046 · wk-form4_1717705009.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,409 F1 · shares: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders. Read SEC document
June 26, 2023 Filed Jun 28, 2023 23:01 UTC	BIOGEN INC. BIIB · Entity 1675	GrantCommon Stock	960	$0.00	$0.00	Disclosure SEC source: 0001127602-23-019543 · form4.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,150 Read SEC document
June 13, 2023 Filed Jun 15, 2023 18:11 UTC	MIMEDX GROUP, INC. MDXG · Entity 5271	GrantCommon Stock	35,354	$4.95	$175,002.30	Disclosure SEC source: 0001376339-23-000038 · wk-form4_1686867074.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,219 F1 · shares: Represents annual restricted stock unit grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders. Read SEC document
June 07, 2023 Filed Jun 8, 2023 18:57 UTC	Bioventus Inc. BVS · Entity 4996	GrantRestricted Stock Units · Derivative	30,400	$0.00	$0.00	Disclosure SEC source: 0001578563-23-000038 · primary_doc.xml · derivative · entry 3 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,400 Underlying: Class A Common Stock · 30,400 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F3 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document
June 06, 2023 Filed Jun 8, 2023 18:57 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionRestricted Stock Units · Derivative	16,648	$0.00	$0.00	Disclosure SEC source: 0001578563-23-000038 · primary_doc.xml · derivative · entry 2 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 16,648 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on June 6, 2023. F2 · derivative.expiration_date: The RSUs vested on June 6, 2023. Read SEC document
June 06, 2023 Filed Jun 8, 2023 18:57 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionClass A Common Stock	16,648	$0.00	$0.00	Disclosure SEC source: 0001578563-23-000038 · primary_doc.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,958 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 25, 2023 Filed May 26, 2023 16:28 UTC	Bioventus Inc. BVS · Entity 4996	PurchaseClass A Common Stock	44,000	$2.66	$117,176.40	Disclosure SEC source: 0001578563-23-000035 · primary_doc.xml · nonDerivative · entry 2 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,310 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $2.57 to $2.71, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
May 24, 2023 Filed May 26, 2023 16:28 UTC	Bioventus Inc. BVS · Entity 4996	PurchaseClass A Common Stock	44,000	$2.69	$118,390.80	Disclosure SEC source: 0001578563-23-000035 · primary_doc.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,310 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $2.61 to $2.78, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
March 14, 2023 Filed Mar 16, 2023 21:19 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionRestricted Stock Units · Derivative	3,949	$0.00	$0.00	Disclosure SEC source: 0000899243-23-008793 · doc4.xml · derivative · entry 3 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 3,949 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vest in full on March 14, 2023. F2 · derivative.expiration_date: The RSUs vest in full on March 14, 2023. Read SEC document
March 14, 2023 Filed Mar 16, 2023 21:19 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionClass A Common Stock	3,949	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-23-008793 · doc4.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. Read SEC document
June 17, 2022 Filed Jun 22, 2022 20:43 UTC	Bioventus Inc. BVS · Entity 4996	GrantRestricted Stock Units · Derivative	16,648	$0.00	$0.00	Disclosure SEC source: 0000899243-22-023648 · doc4.xml · derivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,648 Underlying: Class A Common Stock · 16,648 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Issuer's Board of Directors through the applicable vesting date. F2 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document
June 15, 2022 Filed Jun 17, 2022 20:35 UTC	BIOGEN INC. BIIB · Entity 1675	GrantCommon Stock	1,370	$0.00	$0.00	Disclosure SEC source: 0001127602-22-017781 · form4.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,190 Read SEC document
June 07, 2022 Filed Jun 13, 2022 18:38 UTC	MIMEDX GROUP, INC. MDXG · Entity 5271	GrantCommon Stock	44,191	$3.96	$174,996.36	Disclosure SEC source: 0001376339-22-000092 · wf-form4_165515989823045.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,865 F1 · shares: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders. Read SEC document
April 01, 2022 Filed Apr 5, 2022 21:18 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionRestricted Stock Units · Derivative	40,573	$0.00	$0.00	Disclosure SEC source: 0000899243-22-013968 · doc4.xml · derivative · entry 2 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 40,573 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on April 1, 2022. F2 · derivative.expiration_date: The RSUs vested on April 1, 2022. Read SEC document
April 01, 2022 Filed Apr 5, 2022 21:18 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionClass A Common Stock	40,573	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-013968 · doc4.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. Read SEC document
March 14, 2022 Filed Mar 16, 2023 21:19 UTC	Bioventus Inc. BVS · Entity 4996	GrantRestricted Stock Units · Derivative	3,949	$0.00	$0.00	Disclosure SEC source: 0000899243-23-008793 · doc4.xml · derivative · entry 2 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,949 Underlying: Class A Common Stock · 3,949 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vest in full on March 14, 2023. F2 · derivative.expiration_date: The RSUs vest in full on March 14, 2023. Read SEC document
February 11, 2022 Filed Feb 15, 2022 21:11 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionRestricted Stock Units · Derivative	13,500	$0.00	$0.00	Disclosure SEC source: 0000899243-22-006531 · doc4.xml · derivative · entry 2 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 13,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units vested on February 11, 2022. F2 · derivative.expiration_date: The restricted stock units vested on February 11, 2022. Read SEC document
February 11, 2022 Filed Feb 15, 2022 21:11 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionClass A Common Stock	13,500	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-006531 · doc4.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. Read SEC document
February 10, 2022 Filed Feb 14, 2022 20:31 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionPhantom Profit Units · Derivative	38,288	$0.00	$0.00	Disclosure SEC source: 0000899243-22-006324 · doc4.xml · derivative · entry 2 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 38,288 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Phantom Profit Unit represented a contingent right to receive one share of Class A common stock and vested on the one-year anniversary of the consummation of the Isuser's initial public offering. F1 · derivative.exercise_date: Each Phantom Profit Unit represented a contingent right to receive one share of Class A common stock and vested on the one-year anniversary of the consummation of the Isuser's initial public offering. F1 · derivative.expiration_date: Each Phantom Profit Unit represented a contingent right to receive one share of Class A common stock and vested on the one-year anniversary of the consummation of the Isuser's initial public offering. Read SEC document
February 10, 2022 Filed Feb 14, 2022 20:31 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionClass A Common Stock	38,288	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-006324 · doc4.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Phantom Profit Unit represented a contingent right to receive one share of Class A common stock and vested on the one-year anniversary of the consummation of the Isuser's initial public offering. Read SEC document
July 01, 2021 Filed Jul 2, 2021 21:27 UTC	BIOGEN INC. BIIB · Entity 1675	GrantCommon Stock	775	$0.00	$0.00	Disclosure SEC source: 0001127602-21-021332 · form4.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,820 Read SEC document
May 27, 2021 Filed May 28, 2021 14:31 UTC	MIMEDX GROUP, INC. MDXG · Entity 5271	GrantCommon Stock	17,056	$10.26	$174,994.56	Disclosure SEC source: 0001376339-21-000077 · wf-form4_162222667862680.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,674 F1 · kind: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders. Read SEC document
April 01, 2021 Filed Apr 5, 2021 16:35 UTC	Bioventus Inc. BVS · Entity 4996	GrantRestricted Stock Units · Derivative	40,573	$0.00	$0.00	Disclosure SEC source: 0000899243-21-014840 · doc4.xml · derivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,573 Underlying: Class A Common Stock · 40,573 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest on April 1, 2022 and have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest on April 1, 2022 and have no expiration date. Read SEC document
February 11, 2021 Filed Feb 16, 2021 18:12 UTC	Bioventus Inc. BVS · Entity 4996	GrantRestricted Stock Units · Derivative	13,500	$0.00	$0.00	Disclosure SEC source: 0000899243-21-006747 · doc4.xml · derivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Class A Common Stock · 13,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest on February 11, 2022. F2 · derivative.expiration_date: The restricted stock units vest on February 11, 2022. Read SEC document
January 04, 2021 Filed Jan 6, 2021 10:21 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	GrantCommon Stock	4,005	$0.00	$0.00	Disclosure SEC source: 0001606498-21-000003 · wf-form4_160994647007367.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,197 F1 · shares: Represents restricted share units issued to the reporting person on January 4, 2021 pursuant to the Avanos Medical, Inc. Outside Directors' Compensation Plan. Read SEC document
December 16, 2020 Filed Dec 18, 2020 07:45 UTC	MIMEDX GROUP, INC. MDXG · Entity 5271	GrantCommon Stock	15,964	$7.83	$124,998.12	Disclosure SEC source: 0001376339-20-000155 · wf-form4_160829554252868.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,618 F1 · shares: Represents grant of restricted stock that vess in equal parts on July 21, 2021; July 21, 2022; and July 21, 2023. Read SEC document
October 02, 2020 Filed Oct 5, 2020 16:12 UTC	MIMEDX GROUP, INC. MDXG · Entity 5271	GrantCommon Stock	26,236	$6.67	$174,994.12	Disclosure SEC source: 0001376339-20-000126 · wf-form4_160192873392774.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,654 F1 · shares: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. Award vests after 12 months. Read SEC document
July 21, 2020 Filed Aug 28, 2020 16:42 UTC	MIMEDX GROUP, INC. MDXG · Entity 5271	GrantCommon Stock	13,418	$5.90	$79,166.20	Disclosure SEC source: 0001376339-20-000099 · wf-form4_159864734311202.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,418 F1 · shares: On August 5, 2020, based on the closing stock price on that date ($5.90), the Company fixed the number of shares of common stock subject to a previously-granted restricted stock unit award. Award vests upon the first anniversary of the grant date and will be settled in common stock upon vesting. The grant is exempt under Rule 16b-3. Read SEC document
June 03, 2020 Filed Jun 5, 2020 21:14 UTC	BIOGEN INC. BIIB · Entity 1675	GrantCommon Stock	890	$0.00	$0.00	Disclosure SEC source: 0001127602-20-019021 · form4.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,045 Read SEC document
January 02, 2020 Filed Jan 8, 2020 16:16 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	GrantCommon Stock	5,293	$0.00	$0.00	Disclosure SEC source: 0001606498-20-000004 · wf-form4_157851819821197.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,192 F1 · shares: Represents restricted share units issued to the reporting person on January 2, 2020 pursuant to the Avanos Medical, Inc. Outside Director's Compensation Plan. Read SEC document
June 19, 2019 Filed Jun 20, 2019 22:01 UTC	BIOGEN INC. BIIB · Entity 1675	GrantCommon Stock	1,155	$0.00	$0.00	Disclosure SEC source: 0001127602-19-022434 · form4.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,155 Read SEC document
January 02, 2019 Filed Jan 4, 2019 09:13 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	GrantCommon Stock	4,248	$0.00	$0.00	Disclosure SEC source: 0001606498-19-000003 · wf-form4_154661118307732.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,899 F1 · shares: Represents restricted share units issued to the reporting person on January 2, 2019, pursuant to the Avanos Medical, Inc. Outside Directors' Compensation Plan. Read SEC document
May 03, 2018 Filed May 4, 2018 10:33 UTC	AVANOS MEDICAL, INC. HYH · Entity 28189	GrantCommon Stock	384	$0.00	$0.00	Disclosure SEC source: 0001606498-18-000038 · wf-form4_152544442580212.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,651 F1 · shares: Represents restricted share units issued to the reporting person on May 3, 2018 pursuant to the Halyard Health, Inc. Outside Director's Compensation Plan. Read SEC document
January 02, 2018 Filed Jan 3, 2018 17:09 UTC	AVANOS MEDICAL, INC. HYH · Entity 28189	GrantCommon Stock	2,946	$0.00	$0.00	Disclosure SEC source: 0001606498-18-000008 · wf-form4_151501734382250.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,267 F1 · shares: Represents restricted share units issued to the reporting person on January 2, 2018 pursuant to the Halyard Health, Inc. Outside Director's Compensation Plan. Read SEC document
January 03, 2017 Filed Jan 5, 2017 10:21 UTC	AVANOS MEDICAL, INC. HYH · Entity 28189	GrantCommon Stock	3,749	$0.00	$0.00	Disclosure SEC source: 0001606036-17-000008 · primary_doc.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,047 F1 · shares: Represents restricted share units issued to the reporting person on January 3, 2017 pursuant to the Halyard Health, Inc. Outside Director's Compensation Plan. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.